JP2008525491A5 - - Google Patents

Download PDF

Info

Publication number
JP2008525491A5
JP2008525491A5 JP2007548552A JP2007548552A JP2008525491A5 JP 2008525491 A5 JP2008525491 A5 JP 2008525491A5 JP 2007548552 A JP2007548552 A JP 2007548552A JP 2007548552 A JP2007548552 A JP 2007548552A JP 2008525491 A5 JP2008525491 A5 JP 2008525491A5
Authority
JP
Japan
Prior art keywords
fviii
vwf
construct
life
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007548552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525491A (ja
JP5022231B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/046879 external-priority patent/WO2006071801A2/en
Publication of JP2008525491A publication Critical patent/JP2008525491A/ja
Publication of JP2008525491A5 publication Critical patent/JP2008525491A5/ja
Application granted granted Critical
Publication of JP5022231B2 publication Critical patent/JP5022231B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007548552A 2004-12-27 2005-12-23 ポリマー−フォンビルブラント因子結合体 Expired - Lifetime JP5022231B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US63924404P 2004-12-27 2004-12-27
US60/639,244 2004-12-27
US66837805P 2005-04-04 2005-04-04
US60/668,378 2005-04-04
US67190105P 2005-04-15 2005-04-15
US60/671,901 2005-04-15
US68508605P 2005-05-26 2005-05-26
US60/685,086 2005-05-26
PCT/US2005/046879 WO2006071801A2 (en) 2004-12-27 2005-12-23 Polymer-von willebrand factor-conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012081700A Division JP5715983B2 (ja) 2004-12-27 2012-03-30 ポリマー−フォンビルブラント因子結合体

Publications (3)

Publication Number Publication Date
JP2008525491A JP2008525491A (ja) 2008-07-17
JP2008525491A5 true JP2008525491A5 (enExample) 2009-02-12
JP5022231B2 JP5022231B2 (ja) 2012-09-12

Family

ID=36540284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007548552A Expired - Lifetime JP5022231B2 (ja) 2004-12-27 2005-12-23 ポリマー−フォンビルブラント因子結合体
JP2012081700A Expired - Lifetime JP5715983B2 (ja) 2004-12-27 2012-03-30 ポリマー−フォンビルブラント因子結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012081700A Expired - Lifetime JP5715983B2 (ja) 2004-12-27 2012-03-30 ポリマー−フォンビルブラント因子結合体

Country Status (15)

Country Link
US (4) US7884075B2 (enExample)
EP (1) EP1835938B1 (enExample)
JP (2) JP5022231B2 (enExample)
KR (1) KR20070092754A (enExample)
CN (1) CN101163506B (enExample)
AU (1) AU2005322067B8 (enExample)
BR (1) BRPI0519562A2 (enExample)
CA (1) CA2591852A1 (enExample)
DK (1) DK1835938T3 (enExample)
ES (1) ES2434035T3 (enExample)
IL (1) IL183634A (enExample)
MX (1) MX2007007877A (enExample)
PL (1) PL1835938T3 (enExample)
PT (1) PT1835938E (enExample)
WO (1) WO2006071801A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
CN101557830B (zh) * 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
AU2007340382B2 (en) 2006-12-27 2013-06-27 Nektar Therapeutics Von Willebrand Factor- and Factor VIII-polymer conjugates having a releasable linkage
DK2152735T3 (en) * 2007-05-18 2015-04-20 Baxter Int METHOD FOR PRODUCING mature VWF FROM VWF PRO-PEPTIDE
EP2486936A1 (en) 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
AU2008267360B2 (en) 2007-06-26 2013-09-12 Takeda Pharmaceutical Company Limited Hydrolysable polymeric Fmoc-linker
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
NZ585530A (en) * 2007-12-27 2012-06-29 Baxter Int Methods for differentiating plasma-derived protein from recombinant protein in a sample
AU2008345183B2 (en) 2007-12-27 2014-08-21 Baxalta GmbH Method and compositions for specifically detecting physiologically acceptable polymer molecules
TWI600437B (zh) 2007-12-28 2017-10-01 巴克斯歐塔公司 重組ｖｗｆ調配物
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CA2710567A1 (en) 2007-12-31 2009-07-16 Baxter Healthcare S.A. Transgenic non-human animals expressing human blood clotting factors
WO2009135888A2 (en) * 2008-05-06 2009-11-12 Octapharma Ag Complex
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
KR101200659B1 (ko) * 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
WO2010014258A2 (en) * 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
MX2011004085A (es) 2008-10-17 2011-09-27 Baxter International Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.
EP2337794B1 (en) * 2008-10-20 2013-07-31 USV Limited An improved process for pegylation of proteins
HRP20130414T1 (en) * 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
DK2431741T3 (da) * 2008-10-21 2013-10-21 Baxter Int Fremgangsmåde til bestemmelse af virksomme bestanddele i profarmaka-PEG-proteinkonjugat
AU2009324447B2 (en) * 2008-12-11 2016-02-25 Takeda Pharmaceutical Company Limited Detection of physiologically acceptable polymer molecules using near infrared spectroscopy
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
RU2595442C2 (ru) 2009-07-27 2016-08-27 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US20110072524A1 (en) * 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
HUE026907T2 (en) 2009-08-20 2016-07-28 Baxalta Inc Clean VWF to enhance removal of non-lipid enveloped viruses
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
KR102325780B1 (ko) 2010-07-30 2021-11-12 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
KR101309566B1 (ko) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
CA2836478A1 (en) 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2015021423A2 (en) * 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
WO2015188224A1 (en) 2014-06-13 2015-12-17 Csl Limited Improved production of recombinant von willebrand factor in a bioreactor
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
CN104491917B (zh) * 2014-12-30 2018-01-09 广州市拜特凇医药科技有限公司 一种含有peg或其衍生物的生物材料
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｆｖｉｉｉ因子ポリマー結合体
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
KR20180094114A (ko) 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7307047B2 (ja) 2017-07-07 2023-07-11 武田薬品工業株式会社 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
US20190091298A1 (en) 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
KR20200038309A (ko) 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第ｆｖｉｉｉ因子ポリマー結合体
SG11202009213TA (en) 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
JP2022524291A (ja) 2019-02-01 2022-05-02 武田薬品工業株式会社 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
JP2023514541A (ja) 2020-02-04 2023-04-06 武田薬品工業株式会社 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
WO1993000357A1 (en) * 1991-06-28 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic polypeptides based on von willebrand factor
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
SK282483B6 (sk) 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6127153A (en) 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
AT405740B (de) 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
KR100358276B1 (ko) 1998-03-24 2002-10-25 닛폰 유시 가부시키가이샤 옥시란 유도체 및 이의 제조방법
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
AU6357900A (en) * 1999-07-20 2001-02-05 Amgen, Inc. Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods
SE515295C2 (sv) * 1999-11-23 2001-07-09 Medicarb Ab Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat
AUPR610501A0 (en) 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
WO2005032581A2 (en) * 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
EP1691841B1 (en) * 2003-12-10 2020-09-09 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater

Similar Documents

Publication Publication Date Title
JP2008525491A5 (enExample)
JP6223377B2 (ja) 長期間作用性ペプチド類似体のための組成物
JP6567577B2 (ja) Ｔｆｐｉインヒビターおよび使用法
JP2012126750A5 (enExample)
CA2838833A1 (en) Pro-coagulant compounds and methods of use thereof
JP2009527502A (ja) ペプチドおよびペプチド誘導体ならびにそれらを含有する医薬組成物
US8067533B2 (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
TW201811817A (zh) 血小板反應素１結合肽
CN105828832A (zh) Psd-95的二聚抑制剂的脂肪酸衍生物
JP2000136202A (ja) 新規なヘパリン結合ペプチド
JP2011523634A (ja) ペプチド、ペプチド模倣物およびそれらの誘導体、それらの製造、ならびに治療および／または予防活性のある医薬組成物を調製するためのそれらの使用
JP6549554B2 (ja) コレステロール流出を刺激する、減少した毒性を有するペプチド
ZA200200673B (en) Inhibitors of the integrin avbeta6.
CN107397953A (zh) 非肽基聚合物‑胰岛素多聚体和生产其的方法
US20220118063A1 (en) Methods and compositions related to improved factor viii long half-life coagulation complexes
US20090118195A1 (en) Molecules Which Promote Hematopoiesis
JPH06157588A (ja) 新規な細胞接着活性ペプチド誘導体
AU2008282500A1 (en) Collagen-related peptides and uses thereof